We are live on ! Find out more
EFTR

eFFECTOR Therapeutics, Inc. Common Stock
EFTR

Delisted

EFTR was delisted on the 2nd of July, 2024.

Back to rankings

58 hedge funds and large institutions have $116M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 3

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

44% more capital invested

Capital invested by funds: $80.3M → $116M (+$35.5M)

35% more funds holding

Funds holding: 43 → 58 (+15)

Holders
58
Holders Change
+15
Holders Change %
+34.88%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
15
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$8.36M
2
GCL
Glazer Capital LLC
New York
+$4.8M
3
WAM
Weiss Asset Management
Massachusetts
+$4.24M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.65M
5
HIM
HGC Investment Management
Ontario, Canada
+$2.95M

Top Sellers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
-$2.92M
2
SSA
Schonfeld Strategic Advisors
New York
-$1.24M
3
HighTower Advisors
HighTower Advisors
Illinois
-$240K
4
FTUS
Flow Traders U.S.
New York
-$230K
5
RA
Ramius Advisors
New York
-$168K
Name Holding Trade Value Shares
Change 		Change in
Stake
ECP
1
Empyrean Capital Partners
California
$9.89M – – –
LA
2
Linden Advisors
New York
$8.99M – – –
AC
3
Aristeia Capital
Connecticut
$8.54M +$8.36M +33,975 +5,982%
Citadel Advisors
4
Citadel Advisors
Florida
$5.97M +$3.65M +14,853 +160%
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$4.95M – – –
GCL
6
Glazer Capital LLC
New York
$4.83M +$4.8M +19,516 New
PC
7
Periscope Capital
Ontario, Canada
$4.56M +$12.5K +51 +0.3%
WAM
8
Weiss Asset Management
Massachusetts
$4.26M +$4.24M +17,243 New
RCM
9
Radcliffe Capital Management
Pennsylvania
$3.81M – – –
WP
10
Woodline Partners
California
$3.72M +$926K +3,764 +33%
AFM
11
Anson Funds Management
Texas
$3.25M – – –
SC
12
Sculptor Capital
New York
$3.09M – – –
Hudson Bay Capital Management
13
Hudson Bay Capital Management
Connecticut
$3.05M +$84.1K +342 +3%
LP
14
LMR Partners
United Kingdom
$3.02M +$49K +199 +2%
ACA
15
Arena Capital Advisors
California
$3M +$2.85M +11,576 +2,060%
FTCM
16
Fir Tree Capital Management
New York
$2.97M – – –
HIM
17
HGC Investment Management
Ontario, Canada
$2.97M +$2.95M +12,000 New
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$2.63M – – –
Millennium Management
19
Millennium Management
New York
$2.54M +$2.53M +10,295 New
CH
20
CVI Holdings
Delaware
$1.98M – – –
PSAMP
21
P. Schoenfeld Asset Management (PSAM)
New York
$1.98M – – –
SCC
22
Spring Creek Capital
Kansas
$1.98M +$1.97M +8,000 New
BCM
23
Beryl Capital Management
California
$1.73M +$1.72M +6,997 New
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$1.65M +$1.64M +6,674 New
SCM
25
Saba Capital Management
New York
$1.65M – – –
1
2 3

EFTR Hedge Fund Activity: Q2 2021 in Review

58 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q2 2021, worth a combined $116M — up 44% from $80.3M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new EFTR positions and 5 closed out — a net gain of 15 holders — while 15 added to existing stakes and 3 trimmed.

The largest buyer was Aristeia Capital, adding an estimated $8.36M. The largest seller was Blackstone Inc, exiting entirely with an estimated $2.92M sold.

  • 58 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q2 2021, up from 43 in Q1 2021.
  • Funds reported $116M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q2 2021, up 44% quarter-over-quarter.
  • 20 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q2 2021 and 5 closed out, a net change of +15 holders.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q2 2021 was Aristeia Capital, an estimated $8.36M added.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q2 2021 was Blackstone Inc, an estimated $2.92M sold.

Based on aggregated 13F filings for Q2 2021.